United Therapeutics (NASDAQ:UTHR) Reaches New 52-Week High After Analyst Upgrade

Shares of United Therapeutics Corporation (NASDAQ:UTHR) hit a new 52-week high on Tuesday after TD Cowen raised their price target on the stock from $575.00 to $660.00. TD Cowen currently has a buy rating on the stock. United Therapeutics traded as high as $607.89 and last traded at $588.36, with a volume of 1721854 shares traded. The stock had previously closed at $522.83.

UTHR has been the topic of several other reports. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. HC Wainwright lifted their target price on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $557.64.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $489.91, for a total value of $4,654,145.00. Following the completion of the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at $63,688.30. This trade represents a 98.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 333,820 shares of company stock worth $165,495,478. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 (Tyvaso) pivotal success — the 598‑patient Phase 3 trial met its primary endpoint, showing a Hodges‑Lehmann estimate of +130.1 mL change in absolute FVC at week 52 vs. placebo, a clinically meaningful result that expands Tyvaso’s potential market beyond PAH. Read More.
• Positive Sentiment: Ralinepag Phase 3 readout + buyback momentum — investors are still digesting positive ADVANCE OUTCOMES ralinepag data (large reduction in clinical‑worsening risk) and United Therapeutics’ board authorized up to $2B in buybacks with ~$1.5B in ASRs, which accelerates share‑count reduction and supports EPS. Read More.
• Positive Sentiment: Surge in call‑option activity — unusually large options flow (≈16,800 calls, ~789% above normal) signals bullish positioning and likely amplified intraday upside through speculative buying and short‑covering. (Market data entry)
• Positive Sentiment: Analyst lift — TD Cowen raised its price target to $660 and reiterated a Buy view, which likely reinforced investor conviction after the clinical news. Read More.
• Neutral Sentiment: Read‑through to peers — some smaller respiratory/rare‑disease names saw moves on trial read‑throughs and analyst notes (e.g., Insmed), but the competitive or regulatory implications for other firms remain speculative. Read More.
• Negative Sentiment: Insider selling — CEO Martine Rothblatt sold 9,500 shares on March 26, and public filings show extensive insider sales over recent months; while not unusual for a high‑value stock, heavy insider disposals can be perceived as a headwind by some investors. Read More.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. grew its stake in United Therapeutics by 10.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 127 shares in the last quarter. Corient Private Wealth LLC raised its position in United Therapeutics by 13.5% in the 4th quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock valued at $9,379,000 after purchasing an additional 2,289 shares in the last quarter. Rehmann Capital Advisory Group raised its position in United Therapeutics by 9.8% in the 4th quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock valued at $1,767,000 after purchasing an additional 324 shares in the last quarter. Tobam boosted its stake in shares of United Therapeutics by 28.9% in the 4th quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock valued at $4,803,000 after buying an additional 2,211 shares during the period. Finally, Wick Capital Partners LLC acquired a new position in shares of United Therapeutics during the fourth quarter worth about $297,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Up 12.5%

The stock has a 50-day moving average price of $498.42 and a 200 day moving average price of $474.96. The firm has a market capitalization of $25.79 billion, a price-to-earnings ratio of 21.09, a P/E/G ratio of 1.88 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter last year, the company earned $6.19 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.